Clinical Stage I Esophageal Adenocarcinoma AJCC v8

5

Review clinical trials related to Clinical Stage I Esophageal Adenocarcinoma AJCC v8. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

This phase II trial tests how well itraconazole works in combination with the usual standard of care endoscopy with ablation for the prevention of esophageal cancer in patients who have high-risk Barrett's esophagus (BE). BE is a condition in which the lining of the esophagus changes and becomes more like the tissue that lines the intestine. People with Barrett's esophagus have a higher risk of developing esophageal cancer. Itraconazole is a drug used to prevent or treat fungal infections. Ablation refers to the removal of abnormal tissue using heat. Endoscopy is a procedure for looking at the esophagus using a long, flexible tube called an endoscope, which has a video camera at the end. Radiofrequency ablation is a type of heat therapy that uses radiofrequency energy (similar to microwave heat) to destroy the abnormal tissue in the esophagus. Giving itraconazole in combination with standard of care endoscopy with ablation may improve the effects of ablation and prevent esophageal cancer in patients with high-risk Barrett's esophagus.

Participants needed: 76
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Jul 13, 2026Locations: 6
Eligibility criteria

Participants with history of prior esophagogastroduodenoscopy (EGD) with an esta... [+19]

Current New York Heart Association (NYHA) class III or IV congestive heart failu... [+13]

Status: Recruiting

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.

Participants needed: 300
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: NRG OncologyUpdated: Jun 25, 2026Locations: 96
Eligibility criteria

Histologically proven diagnosis of adenocarcinoma or squamous cell carcinoma of... [+22]

Cervical esophageal cancers arisen from 15-18 cm from the incisors [+10]

Status: Not yet recruiting

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

This phase II trial tests how well itraconazole works in combination with the usual standard of care endoscopy with ablation for the prevention of esophageal cancer in patients who have high-risk Barrett's esophagus (BE). BE is a condition in which the lining of the esophagus changes and becomes more like the tissue that lines the intestine. People with Barrett's esophagus have a higher risk of developing esophageal cancer. Itraconazole is a drug used to prevent or treat fungal infections. Ablation refers to the removal of abnormal tissue using heat. Endoscopy is a procedure for looking at the esophagus using a long, flexible tube called an endoscope, which has a video camera at the end. Radiofrequency ablation is a type of heat therapy that uses radiofrequency energy (similar to microwave heat) to destroy the abnormal tissue in the esophagus. Giving itraconazole in combination with standard of care endoscopy with ablation may improve the effects of ablation and prevent esophageal cancer in patients with high-risk Barrett's esophagus.

Participants needed: 64
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: May 13, 2026Locations: 6
Eligibility criteria

Participants with history of prior esophagogastroduodenoscopy (EGD) with an esta... [+14]

Current New York Heart Association (NYHA) class III or IV congestive heart failu... [+11]

Status: Recruiting

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

This phase II trial tests how well preoperative (prior to surgery) radiation therapy with fluorouracil, oxaliplatin, and leucovorin calcium (FOLFOX) works for the treatment of stage I-III esophageal or gastroesophageal junction adenocarcinoma. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Fluorouracil stops cells from making deoxyribonucleic acid (DNA) and it may kill tumor cells. Leucovorin is not a chemotherapy medication but is given in conjunction with chemotherapy. Leucovorin is used with the chemotherapy medication fluorouracil to enhance the effects of the fluorouracil, in other words, to make the drug work better. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor cells. Giving preoperative hypofractionated radiation with fluorouracil and oxaliplatin may kill more tumor cells in patients with stage I-III esophageal or gastroesophageal junction adenocarcinoma.

Participants needed: 99
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Mayo ClinicUpdated: Apr 20, 2026Locations: 3
Eligibility criteria

Age ≥ 18 years [+8]

Clinical or biopsy-proven distant metastatic disease (AJCC 8th edition stage Tan... [+7]

Status: Not yet recruiting

A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study

This study evaluates how the treatment for gastroesophageal cancer affects physical function in patients who receive chemotherapy as part of their treatment for gastroesophageal cancer.

Participants needed: 72
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Jonsson Comprehensive Cancer CenterUpdated: Apr 8, 2026Locations: 1
Eligibility criteria

* Adults ≥ 18 years old at the start of study treatment. [+3]

* Patients with stage I disease with plans to undergo endoscopic resection or su... [+4]